- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Ovarian Cancer | Clinical
Binimetinib May be Beneficial for Patients With KRAS+ Low-Grade Serous Ovarian Cancer
July 14, 2021
In an interview with Targeted Oncology, Rachel N. Grisham, MD, discussed binimetinib’s effect on patients with ovarian cancer harboring a KRAS mutation.
O’Malley Reviews Standard Therapies for Patients with Platinum-Agnostic Ovarian Cancer
July 09, 2021
David M. O’Malley, MD, discusses the prognosis and historical treatment options for patients with platinum-agnostic ovarian cancer.
Niraparib Makes an Impression in the Frontline Setting of Advanced Ovarian Cancer
June 23, 2021
In an interview with Targeted Oncology, Kathleen Moore, MD, discusses the effects of niraparib for ovarian cancer in the earlier-line setting in more detail and how she anticipates it will change clinical practice.
High-Grade Ovarian Cancer Shows Survival Gap Between HR-Deficient and Proficient BRCA+ Tumors
June 11, 2021
In an interview with Targeted Oncology, held during the 2021 ASCO Annual Meeting, Travis Sims, MD, MPH, discussed the treatment of HRD-positive ovarian cancer and the retrospective analysis of HRD status and its impact of survival outcomes for this patient population.
Mirvetuximab Soravtansine Plus Bevacizumab Yields High Responses in Platinum-Agnostic Ovarian Cancer
June 10, 2021
David M. O’Malley, MD, discusses final analysis data from the phase 1b FORWARD II trial of mirvetuximab soravtansine plus bevacizumab as treatment of patients with platinum-agnostic ovarian cancer.
Phase 3 Efficacy and Safety of Niraparib in BRCA+ Ovarian Cancer
June 08, 2021
Kathleen Moore, MD, discusses the safety and efficacy profile of niraparib, based on data from the phase 3 trials, PRIMA; ENGOT-OV16/NOVA, and NORA.
Survival Benefit Not Improved With Extended Bevacizumab Treatment in Ovarian Cancer
June 07, 2021
Data from the phase 3 AGO-OVAR 17/BOOST/GINECO OV118/ENGOT Ov-15 trial of patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer show that even though prolonged treatment with bevacizumab is feasible and safe, it does not improve survival.
Mirvetuximab Soravtansine Combination Elicits Durable Responses in Recurrent, Platinum Agnostic Ovarian Cancer
June 07, 2021
Results from the final analysis of the phase 1b FORWARD II trail, show that mirvetuximab soravtansine combined with bevacizumab yielded durable responses in patients with recurrent, platinum agnostic ovarian cancer, a population with an unmet need for more effective, non-platinum treatments.
Niraparib Safe and Well Tolerated in Platinum-Sensitive Recurrent Ovarian Cancer
June 05, 2021
Niraparib has an acceptable safety profile for patients with platinum-sensitive recurrent ovarian cancer, regardless of the dose being adjusted for weight, according to updated results from the phase 3 NORMA trial.
Niraparib Maintenance Prolongs PFS in BRCA-Positive Ovarian Cancer
June 04, 2021
In patients with ovarian cancer and BRCA mutations who were enrolled in 3 different trials, maintenance treatment with niraparib improved progression-free survival compared with placebo with no new safety signals.